NLS Global report

IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.

This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.

Stryker has announced a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical for USD 80 per share in cash, representing a total fully diluted equity value of approximately USD 4.9 billion.

Accumulus Synergy’s cloud-based data-sharing platform could accelerate access to vaccines and other health technologies by enabling multi-country regulatory submissions and expediting regulatory review and approval, potentially helping to end future emerging infectious disease outbreaks swiftly and more equitably.

Norwegian company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics – and the company is now ready to test its product in humans.

Lithuanian company Celltechna has opened the first and only gene therapy centre in the Baltic States in Vilnius, Lithuania.